Cancer Immunology

Our group is focused on understanding how the tumor-reactive T cell response, often rendered dysfunctional in cancer, can be improved with adequate support in terms of e.g. immunotherapies. We are in particular interested in the effect of immune checkpoint blockade (ICB) alone or combined with conventional therapies such as chemotherapy. We are investigating the mechanisms of action of these therapies, if all tumor-reactive T cells respond in a similar fashion to therapy, and whether immunocompetence – or lack thereof – influence responsiveness to ICB and the level of immune related adverse events.
In an exploratory project we are investigating whether the composition of ribosomal proteins within ribosomes influences T cell recognition on tumors.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.